The latest price target for Avadel Pharmaceuticals (NASDAQ:AVDL) was reported by Deutsche Bank on February 11, 2025. The analyst firm set a price target for $12.00 expecting AVDL to rise to within 12 months (a possible 43.36% upside). 27 analyst firms have reported ratings in the last year.

The latest analyst rating for Avadel Pharmaceuticals (NASDAQ:AVDL) was provided by Deutsche Bank, and Avadel Pharmaceuticals initiated their buy rating.

The last upgrade for Avadel Pharmaceuticals PLC happened on November 30, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Avadel Pharmaceuticals PLC.

The last downgrade for Avadel Pharmaceuticals PLC happened on August 10, 2022 when Jefferies changed their price target from $6 to $8 for Avadel Pharmaceuticals PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avadel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avadel Pharmaceuticals was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.

While ratings are subjective and will change, the latest Avadel Pharmaceuticals (AVDL) rating was a initiated with a price target of $0.00 to $12.00. The current price Avadel Pharmaceuticals (AVDL) is trading at is $8.37, which is within the analyst’s predicted range.